Charles River Laboratories International, Inc. (CRL) financials

Charles River Laboratories International, Inc. (CRL) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Charles River Laboratories International, Inc. reported revenue of $4.02B, down 0.9% year over year, net income of -$144M, diluted EPS of -$2.91 and free cash flow of $518M.

Revenue (fiscal 2025)

$4.02B

Revenue growth (fiscal 2025)

-0.9%

Net income (fiscal 2025)

-$144M

Diluted EPS (fiscal 2025)

-$2.91

Free cash flow (fiscal 2025)

$518M

Charles River Laboratories International, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001100682, classified as Services-Commercial Physical & Biological Research.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.